DAWN Q3 2023 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$99,000

Operating Income

-$51M

Net Income

-$46M

EPS (Diluted)

$-0.54

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$40M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$414M

Total Liabilities

$25M

Stockholders' Equity

$390M

Cash & Equivalents

$241M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$99,000	-$165,000	+40.0%
Operating Income	-$51M	-$40M	-29.6%
Net Income	-$46M	-$38M	-22.1%